Merck: Gonal-f Approved in Japan for Ovulation Induction in Infertile Women
Merck KGaA announced today that the Japanese Ministry of Health, Labor and Welfare has granted approval to extend the indication of Gonal-f® (follitropin alfa for injection) to infertile women suffering from irregular or no ovulation (oligoovulation or anovulation) due to a dysfunction in the hypothalamic-pituitary system or polycystic ovarian syndrome. Gonal-f is a recombinant follicle-stimulating hormone currently approved in Japan for the treatment of male infertility.
The extended marketing authorization includes Gonal-f in 75 IU (International Units) vial and Gonal-f prefilled pen in 300 IU, 450 IU and 900 IU.
In Japan, Gonal-f has been indicated since 2006 to treat male hypogonadotropic hypogonadism (MHH) in combination with human Chorionic Gonadotropin (hCG), for the induction of spermatogenesis. The supplemental New Drug Application (sNDA) for ovulation induction in females was filed by Merck Serono in October 2008.
GONAL-f is currently approved in 77 countries for the treatment of male infertility and in 100 countries to treat female infertility.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.